A final-stage study, examining if the drug solanezumab slows the cognitive and functional decline of people with mild Alzheimer’s is currently underway in the US.
Previous trials of the drug – made by pharmaceutical giant Eli Lilly – have shown no effect in people with later stages of the disease, but researchers found it had an effect on daily behaviour and functioning of brain and memory in people with earlier-stage disease.
Dr Eric Karran, director of research at Alzheimer’s Research UK, said the results may suggest monthly injections should be given early to ward off the disease – in the same way that people take statins to prevent heart disease.
You can read more about the trial in the Herald Sun here.
This was a very helpful article
Great article, thanks for sharing. Cheers